-
Posted by
Two Blokes Jun 16 -
Filed in
Stock
-
6 views
With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay Journey Program In a clinical trial, adults with obesity or overweight and a weight-related medical condition taking Zepbound 15 mg lost 48 lbs (~21% weight loss) and approximately 1 in 3 on Zepbound 15 mg lost over 58 lbs (25% weight loss) INDIANAPOLIS , June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program.1 Health care providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will begin in early August. With the addition of these doses, every strength of Zepbound vial will be available for $499/month or less ($349 for the 2.5 mg starter dose) to any eligible adult with obesity and a valid prescription, regardless of insurance.
